comparemela.com
Home
Live Updates
New Guideline Gives Active Surveillance a Boost : comparemela.com
New Guideline Gives Active Surveillance a Boost
The 2022 guidance for the first time makes active surveillance the recommended treatment for select patients with favorable intermediate-risk Gleason 3+4 prostate cancer.
Related Keywords
New York ,
United States ,
Memorial Sloan Kettering Cancer Center ,
Ann Arbor ,
Michigan ,
American ,
Rick Davis ,
Jamesa Eastham ,
Todd Morgan ,
Petert Scardino ,
James Schraidt ,
Morgan ,
Ancan Foundation ,
American Society For Radiation Oncology ,
Research Professor ,
American Urological Association ,
National Comprehensive Cancer Network ,
American Society ,
Radiation Oncology ,
New York City ,
Medscape Medical ,
Jack Lapides ,
Michigan Medicine ,
Active Surveillance ,
Localized Prostate Cancer ,
Prostate Carcinoma ,
Alignant Prostate Neoplasm ,
Prostate Cancer ,
Ancer Prostate ,
Clinical Guidelines ,
Guidelines ,
Activism ,
Activist ,
Social Issues ,
Biopsy ,
Chemotherapy ,
Neoadjuvant ,
Clinical Research ,
Clinical Trials ,
Linical Studies ,
Healthcare And Medical Technology ,
Ealth And Medical Tech ,
Ealth And Med Tech ,
Ealth And Medical Technology ,
Cancer Risk ,
Cancer ,
Alignant Neopla ,
comparemela.com © 2020. All Rights Reserved.